RT Book, Section
A1 Isakoff, Steven J.
A2 Chabner, Bruce A.
A2 Longo, Dan L.
SR Print(0)
ID 1127649621
T1 Metastatic Breast Cancer
T2 Harrison's Manual of Oncology, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071793254
LK hemonc.mhmedical.com/content.aspx?aid=1127649621
RD 2024/04/19
AB Since  1990,  the  annual  rate  of  breast  cancer  death  has  been  decreasing  by  approximately  2.2%  per  year  (1).  Historically,  median  survival  of  patients  with  metastatic  breast  cancer  (MBC)  was  estimated  to  be  18–30  months.  Many  experts  agree  that  median  survival  has  improved  in  recent  years  beyond  30  months,  although  survival  varies  significantly  by  breast  cancer  subtype.  A  number  of  newer  active  agents  have  recently  been  added  to  the  armamentarium  against  breast  cancer,  including  third-generation  aromatase  inhibitors,  novel  antimicrotubule  chemotherapy  agents,  and  biologic  agents  such  as  lapatinib,  pertuzumab,  and  everolimus.  Despite  these  advances,  breast  cancer  remains  the  second  leading  cause  of  cancer  death  in  women  in  the  United  States,  with  39,620  women  estimated  to  die  of  breast  cancer  in  2013  (1).